Respiratory News and Research

RSS

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Mobility tracking using cell phone data showing greater movement of people is a strong predictor of increased rates of COVID-19, according to new data in CMAJ (Canadian Medical Association Journal)

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

Cross-border asthma study investigates hygiene hypothesis amid COVID-19 pandemic

A cross-border investigation of children's susceptibility to asthma and other childhood illnesses in the United States and Mexico is the focus of a new study led by researchers in the Asthma and Airway Disease Research Center at the University of Arizona Health Sciences.

8 Apr 2021

The interaction between blood clotting and SARS-CoV-2 infection

Coagulopathy - a condition in which the blood's ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagulation factors in the SARS-CoV-2 infection. Their recent study is posted on the bioRxiv server.

7 Apr 2021

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

A new Morbidity and Mortality Weekly Report published by the U.S. Centers for Disease Control and Prevention (CDC) states that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infection in the real world. The report is based on a CDC study where it routinely tested prospective cohorts of health care professionals, first responders, and essential and frontline workers for SARS-CoV-2 infections.

7 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

In a carefully controlled study, Michigan Medicine researchers will kick off the first national trial to study allergic reactions to the COVID-19 mRNA vaccines.

7 Apr 2021

Unique fungal environment in the lungs

The lungs were for a long time considered to be sterile in health, while in diseases like chronic obstructive pulmonary disease (COPD) failure in immune mechanisms were thought to allow microorganisms to proliferate and persist.

7 Apr 2021

Urolithin A shows promise to slow progression of Duchenne Muscle Dystrophy

Progression of Duchenne Muscle Dystrophy (DMD) can be delayed in mice by supplementing their diets with Urolithin A, according to new results reported today.

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

Researchers at the Infection Biology Unit, German Primate Center, and the Georg-August-University Göttingen in Germany have found that the B.1.351 and P.1 SARS-CoV-2 variants have the potential to evade therapeutic antibodies or antibodies induced by natural infection or vaccination.

7 Apr 2021

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study

UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe.

7 Apr 2021

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

Though the U.S. and South Korea recorded their first official COVID-19 case on the same day, January 20, 2020, there were notable differences in how each country would ultimately address what has become the world's most severe pandemic since 1918.

7 Apr 2021

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

The coronavirus disease (COVID-19) first emerged in late December 2019 in Wuhan, China. Though it has been more than one year since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported, it is still unclear how long the antibodies persist in those who have recovered.

7 Apr 2021

Respiratory News and Research

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Cross-border asthma study investigates hygiene hypothesis amid COVID-19 pandemic

The interaction between blood clotting and SARS-CoV-2 infection

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

Unique fungal environment in the lungs

Urolithin A shows promise to slow progression of Duchenne Muscle Dystrophy

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

South African and Brazilian SARS-CoV-2 variants can evade antibodies from therapies, vaccines, and infection

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study

Researchers use South Korea Data to create new framework for COVID-19-vulnerable locales

70% of SARS-CoV-2 infected in Wuhan still have IgG antibodies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News